# A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

> **NCT01376245** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 646 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone furoate/vilanterol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01376245
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 646 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376245, "A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01376245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*